Authors:
Hanrahan, JR
Mewett, KN
Chebib, M
Burden, PM
Johnston, GAR
Citation: Jr. Hanrahan et al., An improved, versatile synthesis of the GABA(C) antagonists (1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid (TPMPA) and (piperidin-4-yl)methylphosphinic acid (P4MPA), J CHEM S P1, (19), 2001, pp. 2389-2392
Authors:
Chebib, M
Duke, RK
Allan, RD
Johnston, GAR
Citation: M. Chebib et al., The effects of cyclopentane and cyclopentene analogues of GABA at recombinant GABA(C) receptors, EUR J PHARM, 430(2-3), 2001, pp. 185-192
Citation: M. Chebib et al., 1-phenylpyrazolo[3,4-d]pyrimidines; Structure-activity relationships for C6 substituents at A(1) and A(2A) adenosine receptors, BIO MED CH, 8(11), 2000, pp. 2581-2590
Authors:
Lieb, I
Chebib, M
Cooper, B
Dias, LS
Balcar, VJ
Citation: I. Lieb et al., Quantitative autoradiography of Na+-dependent [H-3]L-aspartate binding to L-glutamate transporters in rat brain: structure-activity studies using L-trans-pyrrolidine-2,4-dicarboxylate (L-t-PDC) and 2-(carboxycyclopropyl)-glycine (CCG), NEUROCHEM I, 36(4-5), 2000, pp. 319-327
Authors:
Duke, RK
Chebib, M
Balcar, VJ
Allan, RD
Mewett, KN
Johnston, GAR
Citation: Rk. Duke et al., (+)- and (-)-cis-2-Aminomethylcyclopropanecarboxy acids show opposite pharmacology at recombinant rho(1) and rho(2) GABA(C) receptors, J NEUROCHEM, 75(6), 2000, pp. 2602-2610
Citation: M. Chebib et Gar. Johnston, GABA-activated ligand gated ion channels: Medicinal chemistry and molecular biology, J MED CHEM, 43(8), 2000, pp. 1427-1447
Authors:
Chebib, M
Johnston, GAR
Mattsson, JP
Rydstrom, K
Nilsson, K
Qiu, J
Stevenson, SH
Silverman, RB
Citation: M. Chebib et al., Aminomethyl-2,6-difluorophenols as a novel class of increased lipophilicity GABA(C) receptor antagonists, BIOORG MED, 9(21), 1999, pp. 3093-3098
Authors:
Johnston, GAR
Chebib, M
Duke, RK
Mewett, KN
Mitrovic, AD
Vandenberg, RJ
Citation: Gar. Johnston et al., Medicinal chemistry and molecular pharmacology of GABA receptors and glutamate transporters - Complementary structure-activity relationships, DRUG DEV R, 46(3-4), 1999, pp. 255-260